Skip to content

Study · Non-randomized trial · n = 45 · 2021

5 results

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.

Urva S, Quinlan T, Landry J, Martin J, Loghin C

Clinical pharmacokinetics29 Mar 2021Cited by 46 (Europe PMC)

PMID33778934 (opens in a new tab)PMCIDPMC8332596 (opens in a new tab)DOI10.1007/s40262-021-01012-2 (opens in a new tab)PepBankPUB-33778934
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In adults with renal impairment, tirzepatide exposure after a single 5 mg dose was similar to that in healthy subjects.

    In plain wordsIn people with kidney impairment, a single tirzepatide 5 mg dose gave blood levels similar to those in healthy people.

    Peptide
    Tirzepatide
    Outcome
    No significant changeTirzepatide exposure across renal function groups
    Study

    n = 45

    Comparator
    Normal renal function
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    5 mg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide exposure was similar across renal impairment groups and healthy subjects.
    1 context sentence
    Summary · context
    received a single subcutaneous dose of tirzepatide 5 mg.
  2. 02HumanNon-randomized trialPharmacokinetics

    In adults with renal impairment, the 90% confidence intervals of AUC and Cmax ratios versus normal renal function spanned unity, except for the moderate group AUCs.

    In plain wordsIn people with kidney impairment, tirzepatide blood levels did not differ from healthy people, except slightly higher total exposure in moderate impairment.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAUC and Cmax ratios, renal impairment vs normal function
    Study

    n = 45

    Comparator
    Normal renal function
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    5 mg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    The 90% CI of ratios of AUCs and Cmax comparing each renal impairment group versus normal renal function spanned unity, except for a 25-29% increase in AUCs in the moderate renal impairment group.
    1 context sentence
    Summary · context
    received a single subcutaneous dose of tirzepatide 5 mg.
  3. 03HumanNon-randomized trialPharmacokinetics

    In adults with and without renal impairment, there was no significant relationship between tirzepatide exposure and eGFR.

    In plain wordsIn people with and without kidney impairment, tirzepatide blood levels were not significantly linked to kidney filtration rate.

    Peptide
    Tirzepatide
    Outcome
    No significant changeRelationship of exposure with eGFR
    Study

    n = 45

    Outcome group
    Pharmacokinetics · Kidney and urinary
    Studied dose
    5 mg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    There was no significant relationship between tirzepatide exposure and eGFR.
    1 context sentence
    Summary · context
    received a single subcutaneous dose of tirzepatide 5 mg.
  4. 04HumanNon-randomized trialSafety outcome

    In adults with renal impairment or normal renal function, few adverse events were reported after a single dose of tirzepatide; most were mild and gastrointestinal in the renal impairment groups.

    In plain wordsIn people with and without kidney impairment, few side effects followed a single tirzepatide dose; most were mild gut problems in the impairment groups.

    Peptide
    Tirzepatide
    Outcome
    Not applicableAdverse events
    Study

    n = 45

    Outcome group
    Adverse events · Whole body
    Studied dose
    5 mg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Few adverse events were reported across the renal impairment and normal renal function groups.
    2 context sentences
    Summary · context
    The majority were mild in severity and of a gastrointestinal nature in the renal impairment groups.
    Summary · context
    received a single subcutaneous dose of tirzepatide 5 mg.
  5. 05HumanNon-randomized trialPharmacokinetics

    In adults with moderate renal impairment, tirzepatide AUC was 25-29% higher than in subjects with normal renal function.

    In plain wordsIn people with moderate kidney impairment, total tirzepatide exposure was about 25-29% higher than in people with normal kidney function.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAUC in moderate renal impairment
    Study

    n: not reported in source

    Comparator
    Normal renal function
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    5 mg · subcutaneous · single doseAs given in this study (human).

    Measurements

    AUC increase
    25 to 29%
    moderate renal impairment

    Source sentences

    Summary
    except for a 25-29% increase in AUCs in the moderate renal impairment group.
    1 context sentence
    Summary · context
    received a single subcutaneous dose of tirzepatide 5 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1Results postedNCT03482024

A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function

Eli Lilly and Companyn = 4530 Mar 2018 to 19 Aug 2019

Renal Insufficiency · End Stage Renal Disease

Trial pageClinicalTrials.govUpdated 23 Mar 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.